New Ural insulin pens may hit European markets

Ural scientists have developed a next gen insulin pen which is meant for free distribution among diabetes patients in the region and for exports to the CIS and the EU.

Ural scientists have developed a next gen insulin pen, a device used to inject insulin for the treatment of pancreatic diabetes, Remedium.ru reported. The new device came from the labs of Medsintez, a Novouralsk-based biotech company participating in the recently formed Ural biopharma cluster. Experts believe the technology is viable enough to compete with international analogs. Alexander Petrov, a member of the healthcare committee in Russia?s State Duma (lower house of Parliament), told Remedium that following the positive decision on Medsintez?s patent application in Russia ??the price of an imported insulin pen set nosedived from $40 to less than $25 apiece.? Mr. Petrov also pointed out that the Novouralsk company ?takes part in tenders on its own, bringing no go-betweens which typically add another 20% to the price...